IMV announces updated data for Phase 2 DPX-Survivac trial in r/r DLBCL
Category: #health  | By Mateen Dalal  | Date: 2019-12-10 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

IMV announces updated data for Phase 2 DPX-Survivac trial in r/r DLBCL
  • The updated results were presented in poster session at the ASH annual meeting
     
  • The study shows strong data for DPX-Survivac in combination with pembrolizumab

IMV Inc., a clinical-stage biopharmaceutical firm focusing on immunotherapy in oncology, recently announced updated results from SPiReL, which is an ongoing Phase 2 study of DPX-Survivac combined with pembrolizumab in patients suffering from refractory/ recurrent diffuse large B-cell lymphoma (r/r DLBCL). These updated results were presented through a poster session in Florida, at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando.

Apparently, the poster consisted of an additional data arranged between the presentation and the submission of the abstract, as it continued to show a positive therapeutic profile as well as clinical benefit for r/r DLBCL patients associated with the treatment, who had received the combination regimen of DPX-Survivac.

Lead investigator of the clinical trial, Neil Berinstein, MD, FFCPC, ABIM and a hematologist at Toronto’s Sunnybrook Health Sciences Centre commented that the updated data exhibit favorable activity in patients who were treated with a combination regimen of DPX-Survivac for refractory/ recurrent diffuse large B-cell lymphoma.

Berinstein further added that as a contrast to both standard-of-care treatments as well as various other immunotherapeutic approaches for development, observation of the clinical advantage besides a safety profile shows the potential of DPX-Survivac to be able to reach out to a population of patients in a dire need of better options for treatment.

Chief Medical Officer at IMV, Joanne Schindler, M.D., D.V.M., stated that the results show a sturdy response in patients getting evaluated who followed the combination regimen consisting DPX-Survivac. It has continued to show a positive therapeutic profile especially for patients who were suffering from hard-to-treat cancers.

Schindler continued that the data validates the novel mechanism of DPX-Survivac that extends the earlier documented results for solid cancers to now surviving-expressing hematologic diseases. The company believes that it represents a meaningful alternative to chemotherapy regimens that are more toxic. The company is looking forward to obtaining topline results from the study as it prepares to introduce IMV-sponsored study in 2020 for r/r DLBCL.

 

Source Credit- https://ir.imv-inc.com/news-releases/news-release-details/updated-clinical-data-phase-2-spirel-study-evaluating-dpx

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

By Mateen Dalal

American chemical company DuPont de Nemours Inc. reportedly signed a definitive agreement to buy out Spectrum Plastics Group from AEA Investors, a U.S. based private equity firm. The acquisition will reinforce DuPont’s position in booming non-c...